Northpond Ventures — 2020 Investments

3 investments dated 2020 · listed companies and verified rows first · show all

Inflammatix, Inc.inflammatix.com in 𝕏Jan 2020✓ verified

Inflammatix develops host-response-based molecular diagnostics tests to identify acute infections and sepsis in emergency and critical care settings.

AI & Machine LearningBiotechHealthtechMedical DevicesBurlingame, US

Tim Sweeney(Co-Founder and CEO)inPurvesh Khatri(Founder)inJONATHAN ROMANOWSKY(Co-Founder)inTimothy Sweeney(Founder)

BoardKENNETH BAHK(Director)MICHAEL RUBIN(Director)

Co-investorsKhosla Ventures Initiate Venture Partners Marram Ventures OSF Ventures StartX DFJ

IsoPlexisisoplexis.comDec 2020

IsoPlexis offers the Cell Analysis Suite (CAS), software for its Beacon optofluidic platform that lets researchers design, automate, and analyze functional live single-cell workflows.

AI & Machine LearningBiotechDeep TechMedical DevicesSaaSNew Haven, US

Rong Fan(Director)Sean McKay(Executive Officer, Director)Sean Mackay(Executive Officer, Director)inRaj KhakharinJing Zhouin

BoardDaniel Wagner(Director)

Board seatSharon Kedar· per SEC Form D

Co-investorsConnecticut Innovations Ally Bridge Group Ironwood Capital Spring Mountain Capital

Triumvira Immunologicstriumvira.com in 𝕏Aug 2020 · $55M

Triumvira is a clinical-stage immuno-oncology company developing autologous and allogeneic T cell therapeutics for cancer treatment.

BiotechHealthtechMedical DevicesAustin, US

TERESA MCROBERTS(Executive Officer)inPAUL LAMMERS, MD, MSc(Executive Officer, Director)inJON IRVIN(Executive Officer)in

BoardDANIEL JANSE(Director)JURGEN ECKHARDT(Director)ELIZABETH WILLIAMS(Director)

Co-investorsATEM Capital Fund B Capital Group B4 Capital Checkmate Capital Group LLC Leaps by Bayer Oceanpine Capital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.